The evidence suggests that treatment of persons with T2D and CKD should consist of triple therapy with renin-angiotensin system blockade (ACE inhibitors or ARBs), SGLT2 inhibitors and finerenone, to slow the progression of CKD and reduce the risk of developing CV complications. This evidence concerns the gene ACE and chronic kidney disease.